XML 39 R32.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Product Sales Analysis - Current Quarter (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2018 | Mar. 31, 2018 | Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Jun. 30, 2018
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 5,030 | $ 4,985 | $ 5,487 | $ 4,882 | $ 4,940 | $ 4,843 | $ 5,260 | $ 5,025 | $ 5,469 | $ 5,565 | $ 10,015
Actual %, year-on-year | 2.00% |  |  |  |  |  |  |  |  |  | 2.00%
CER %, year-on-year | (1.00%) |  |  |  |  |  |  |  |  |  | (2.00%)
Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 1,659 |  |  |  |  |  |  |  |  |  | $ 3,424
Actual %, year-on-year | 15.00% |  |  |  |  |  |  |  |  |  | 14.00%
CER %, year-on-year | 12.00% |  |  |  |  |  |  |  |  |  | 10.00%
US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 1,615 |  |  |  |  |  |  |  |  |  | $ 3,102
Actual %, year-on-year | 6.00% |  |  |  |  |  |  |  |  |  | 3.00%
Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 1,033 |  |  |  |  |  |  |  |  |  | $ 2,154
Actual %, year-on-year | (10.00%) |  |  |  |  |  |  |  |  |  | (5.00%)
CER %, year-on-year | (17.00%) |  |  |  |  |  |  |  |  |  | (14.00%)
Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 723 |  |  |  |  |  |  |  |  |  | $ 1,335
Actual %, year-on-year | (13.00%) |  |  |  |  |  |  |  |  |  | (11.00%)
CER %, year-on-year | (15.00%) |  |  |  |  |  |  |  |  |  | (14.00%)
Oncology |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 1,434 | 1,230 | 1,120 | 1,026 | 993 | 885 | 930 | 867 | 848 | 738 | $ 2,664
Actual %, year-on-year | 44.00% |  |  |  |  |  |  |  |  |  | 42.00%
CER %, year-on-year | 40.00% |  |  |  |  |  |  |  |  |  | 37.00%
Oncology | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 384 |  |  |  |  |  |  |  |  |  | $ 747
Actual %, year-on-year | 42.00% |  |  |  |  |  |  |  |  |  | 43.00%
CER %, year-on-year | 37.00% |  |  |  |  |  |  |  |  |  | 37.00%
Oncology | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 538 |  |  |  |  |  |  |  |  |  | $ 964
Actual %, year-on-year | 112.00% |  |  |  |  |  |  |  |  |  | 91.00%
Oncology | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 256 |  |  |  |  |  |  |  |  |  | $ 505
Actual %, year-on-year | 10.00% |  |  |  |  |  |  |  |  |  | 21.00%
CER %, year-on-year | 1.00% |  |  |  |  |  |  |  |  |  | 9.00%
Oncology | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 256 |  |  |  |  |  |  |  |  |  | $ 448
Actual %, year-on-year | 8.00% |  |  |  |  |  |  |  |  |  | 4.00%
CER %, year-on-year | 6.00% |  |  |  |  |  |  |  |  |  |
Tagrisso |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 422 | 338 | 304 | 248 | 232 | 171 | 147 | 133 | 92 | 51 | $ 760
Actual %, year-on-year | 82.00% |  |  |  |  |  |  |  |  |  | 89.00%
CER %, year-on-year | 77.00% |  |  |  |  |  |  |  |  |  | 82.00%
Tagrisso | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 88 |  |  |  |  |  |  |  |  |  | $ 159
Tagrisso | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 194 |  |  |  |  |  |  |  |  |  | $ 341
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | 89.00%
Tagrisso | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 70 |  |  |  |  |  |  |  |  |  | $ 139
Actual %, year-on-year | 71.00% |  |  |  |  |  |  |  |  |  | 83.00%
CER %, year-on-year | 54.00% |  |  |  |  |  |  |  |  |  | 63.00%
Tagrisso | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 70 |  |  |  |  |  |  |  |  |  | $ 121
Actual %, year-on-year | 4.00% |  |  |  |  |  |  |  |  |  | 13.00%
CER %, year-on-year | 1.00% |  |  |  |  |  |  |  |  |  | 9.00%
Iressa |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 143 | 132 | 130 | 137 | 137 | 124 | 118 | 125 | 135 | 135 | $ 275
Actual %, year-on-year | 4.00% |  |  |  |  |  |  |  |  |  | 5.00%
CER %, year-on-year | (1.00%) |  |  |  |  |  |  |  |  |  | (1.00%)
Iressa | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 77 |  |  |  |  |  |  |  |  |  | $ 148
Actual %, year-on-year | 13.00% |  |  |  |  |  |  |  |  |  | 15.00%
CER %, year-on-year | 7.00% |  |  |  |  |  |  |  |  |  | 8.00%
Iressa | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 6 |  |  |  |  |  |  |  |  |  | $ 14
Actual %, year-on-year | (33.00%) |  |  |  |  |  |  |  |  |  | (18.00%)
Iressa | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 31 |  |  |  |  |  |  |  |  |  | $ 61
Actual %, year-on-year | 11.00% |  |  |  |  |  |  |  |  |  | 13.00%
CER %, year-on-year |  |  |  |  |  |  |  |  |  |  | 2.00%
Iressa | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 29 |  |  |  |  |  |  |  |  |  | $ 52
Actual %, year-on-year | (9.00%) |  |  |  |  |  |  |  |  |  | (15.00%)
CER %, year-on-year | (13.00%) |  |  |  |  |  |  |  |  |  | (18.00%)
Lynparza |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 150 | 119 | 100 | 81 | 59 | 57 | 62 | 58 | 54 | 44 | $ 269
Lynparza | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 10 |  |  |  |  |  |  |  |  |  | 18
Lynparza | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 83 |  |  |  |  |  |  |  |  |  | 149
Lynparza | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 45 |  |  |  |  |  |  |  |  |  | $ 87
Actual %, year-on-year | 36.00% |  |  |  |  |  |  |  |  |  | 50.00%
CER %, year-on-year | 30.00% |  |  |  |  |  |  |  |  |  | 36.00%
Lynparza | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 12 |  |  |  |  |  |  |  |  |  | $ 15
Imfinzi |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 122 | 62 | 18 |  | 1 |  |  |  |  |  | 184
Imfinzi | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 3 |  |  |  |  |  |  |  |  |  | 3
Imfinzi | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 116 |  |  |  |  |  |  |  |  |  | 178
Imfinzi | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 3 |  |  |  |  |  |  |  |  |  | 3
Calquence |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 12 | 8 | 3 |  |  |  |  |  |  |  | 20
Calquence | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 12 |  |  |  |  |  |  |  |  |  | 20
Faslodex |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 247 | 254 | 238 | 241 | 248 | 214 | 222 | 207 | 211 | 190 | $ 501
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | 8.00%
CER %, year-on-year | (3.00%) |  |  |  |  |  |  |  |  |  | 5.00%
Faslodex | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 32 |  |  |  |  |  |  |  |  |  | $ 71
Actual %, year-on-year | 19.00% |  |  |  |  |  |  |  |  |  | 31.00%
CER %, year-on-year | 19.00% |  |  |  |  |  |  |  |  |  | 30.00%
Faslodex | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 125 |  |  |  |  |  |  |  |  |  | $ 259
Actual %, year-on-year | 2.00% |  |  |  |  |  |  |  |  |  | 7.00%
Faslodex | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 59 |  |  |  |  |  |  |  |  |  | $ 118
Actual %, year-on-year | (25.00%) |  |  |  |  |  |  |  |  |  | (11.00%)
CER %, year-on-year | (32.00%) |  |  |  |  |  |  |  |  |  | (21.00%)
Faslodex | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 31 |  |  |  |  |  |  |  |  |  | $ 53
Actual %, year-on-year | 63.00% |  |  |  |  |  |  |  |  |  | 56.00%
CER %, year-on-year | 58.00% |  |  |  |  |  |  |  |  |  | 50.00%
Zoladex |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 192 | 184 | 187 | 185 | 178 | 185 | 235 | 199 | 204 | 178 | $ 376
Actual %, year-on-year | 8.00% |  |  |  |  |  |  |  |  |  | 4.00%
CER %, year-on-year | 4.00% |  |  |  |  |  |  |  |  |  | (1.00%)
Zoladex | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 101 |  |  |  |  |  |  |  |  |  | $ 202
Actual %, year-on-year | 25.00% |  |  |  |  |  |  |  |  |  | 20.00%
CER %, year-on-year | 23.00% |  |  |  |  |  |  |  |  |  | 17.00%
Zoladex | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 2 |  |  |  |  |  |  |  |  |  | $ 3
Actual %, year-on-year | (67.00%) |  |  |  |  |  |  |  |  |  | (79.00%)
Zoladex | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 34 |  |  |  |  |  |  |  |  |  | $ 68
Actual %, year-on-year | (3.00%) |  |  |  |  |  |  |  |  |  | 1.00%
CER %, year-on-year | (14.00%) |  |  |  |  |  |  |  |  |  | (9.00%)
Zoladex | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 55 |  |  |  |  |  |  |  |  |  | $ 103
Actual %, year-on-year | (2.00%) |  |  |  |  |  |  |  |  |  | (10.00%)
CER %, year-on-year | (5.00%) |  |  |  |  |  |  |  |  |  | (13.00%)
Arimidex |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 57 | 54 | 57 | 54 | 54 | 52 | 57 | 56 | 62 | 57 | $ 111
Actual %, year-on-year | 6.00% |  |  |  |  |  |  |  |  |  | 5.00%
CER %, year-on-year | 2.00% |  |  |  |  |  |  |  |  |  |
Arimidex | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 36 |  |  |  |  |  |  |  |  |  | $ 71
Actual %, year-on-year | 29.00% |  |  |  |  |  |  |  |  |  | 25.00%
CER %, year-on-year | 29.00% |  |  |  |  |  |  |  |  |  | 19.00%
Arimidex | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 7 |  |  |  |  |  |  |  |  |  | $ 15
Actual %, year-on-year | (22.00%) |  |  |  |  |  |  |  |  |  | (12.00%)
CER %, year-on-year | (33.00%) |  |  |  |  |  |  |  |  |  | (18.00%)
Arimidex | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 14 |  |  |  |  |  |  |  |  |  | $ 25
Actual %, year-on-year | (7.00%) |  |  |  |  |  |  |  |  |  | (14.00%)
CER %, year-on-year | (13.00%) |  |  |  |  |  |  |  |  |  | (17.00%)
Casodex |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 52 | 52 | 54 | 51 | 54 | 56 | 60 | 62 | 63 | 62 | $ 104
Actual %, year-on-year | (4.00%) |  |  |  |  |  |  |  |  |  | (5.00%)
CER %, year-on-year | (9.00%) |  |  |  |  |  |  |  |  |  | (11.00%)
Casodex | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 28 |  |  |  |  |  |  |  |  |  | $ 59
Actual %, year-on-year | 8.00% |  |  |  |  |  |  |  |  |  | 5.00%
CER %, year-on-year | (4.00%) |  |  |  |  |  |  |  |  |  | (4.00%)
Casodex | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 5 |  |  |  |  |  |  |  |  |  | $ 11
Casodex | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 19 |  |  |  |  |  |  |  |  |  | $ 34
Actual %, year-on-year | (17.00%) |  |  |  |  |  |  |  |  |  | (21.00%)
CER %, year-on-year | (17.00%) |  |  |  |  |  |  |  |  |  | (23.00%)
Oncology, Others |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 37 | 27 | 29 | 29 | 30 | 26 | 29 | 27 | 27 | 21 | $ 64
Actual %, year-on-year | 23.00% |  |  |  |  |  |  |  |  |  | 14.00%
CER %, year-on-year | 23.00% |  |  |  |  |  |  |  |  |  | 11.00%
Oncology, Others | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 9 |  |  |  |  |  |  |  |  |  | $ 16
Actual %, year-on-year | 50.00% |  |  |  |  |  |  |  |  |  | 23.00%
CER %, year-on-year | 50.00% |  |  |  |  |  |  |  |  |  | 15.00%
Oncology, Others | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 2 |  |  |  |  |  |  |  |  |  | $ 3
Oncology, Others | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 26 |  |  |  |  |  |  |  |  |  | $ 45
Actual %, year-on-year | 18.00% |  |  |  |  |  |  |  |  |  | 13.00%
CER %, year-on-year | 18.00% |  |  |  |  |  |  |  |  |  | 10.00%
CVRM |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 1,623 | 1,645 | 1,939 | 1,773 | 1,775 | 1,779 | 1,811 | 1,845 | 2,168 | 2,292 | $ 3,268
Actual %, year-on-year | (9.00%) |  |  |  |  |  |  |  |  |  | (8.00%)
CER %, year-on-year | (11.00%) |  |  |  |  |  |  |  |  |  | (11.00%)
CVRM | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 636 |  |  |  |  |  |  |  |  |  | $ 1,334
Actual %, year-on-year | 11.00% |  |  |  |  |  |  |  |  |  | 14.00%
CER %, year-on-year | 9.00% |  |  |  |  |  |  |  |  |  | 10.00%
CVRM | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 532 |  |  |  |  |  |  |  |  |  | $ 1,029
Actual %, year-on-year | (1.00%) |  |  |  |  |  |  |  |  |  | (7.00%)
CVRM | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 306 |  |  |  |  |  |  |  |  |  | $ 632
Actual %, year-on-year | (26.00%) |  |  |  |  |  |  |  |  |  | (25.00%)
CER %, year-on-year | (33.00%) |  |  |  |  |  |  |  |  |  | (33.00%)
CVRM | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 149 |  |  |  |  |  |  |  |  |  | $ 273
Actual %, year-on-year | (40.00%) |  |  |  |  |  |  |  |  |  | (38.00%)
CER %, year-on-year | (42.00%) |  |  |  |  |  |  |  |  |  | (40.00%)
Brilinta |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 316 | 293 | 299 | 284 | 272 | 224 | 236 | 208 | 214 | 181 | $ 609
Actual %, year-on-year | 16.00% |  |  |  |  |  |  |  |  |  | 23.00%
CER %, year-on-year | 13.00% |  |  |  |  |  |  |  |  |  | 18.00%
Brilinta | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 72 |  |  |  |  |  |  |  |  |  | $ 148
Actual %, year-on-year | 18.00% |  |  |  |  |  |  |  |  |  | 22.00%
CER %, year-on-year | 15.00% |  |  |  |  |  |  |  |  |  | 17.00%
Brilinta | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 144 |  |  |  |  |  |  |  |  |  | $ 259
Actual %, year-on-year | 13.00% |  |  |  |  |  |  |  |  |  | 20.00%
Brilinta | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 86 |  |  |  |  |  |  |  |  |  | $ 172
Actual %, year-on-year | 23.00% |  |  |  |  |  |  |  |  |  | 27.00%
CER %, year-on-year | 13.00% |  |  |  |  |  |  |  |  |  | 14.00%
Brilinta | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 14 |  |  |  |  |  |  |  |  |  | $ 30
Actual %, year-on-year | 8.00% |  |  |  |  |  |  |  |  |  | 20.00%
CER %, year-on-year |  |  |  |  |  |  |  |  |  |  | 16.00%
Farxiga |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 340 | 299 | 332 | 285 | 250 | 207 | 239 | 220 | 211 | 165 | $ 639
Actual %, year-on-year | 36.00% |  |  |  |  |  |  |  |  |  | 40.00%
CER %, year-on-year | 34.00% |  |  |  |  |  |  |  |  |  | 36.00%
Farxiga | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 88 |  |  |  |  |  |  |  |  |  | $ 157
Actual %, year-on-year | 52.00% |  |  |  |  |  |  |  |  |  | 57.00%
CER %, year-on-year | 57.00% |  |  |  |  |  |  |  |  |  | 59.00%
Farxiga | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 139 |  |  |  |  |  |  |  |  |  | $ 266
Actual %, year-on-year | 26.00% |  |  |  |  |  |  |  |  |  | 29.00%
Farxiga | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 78 |  |  |  |  |  |  |  |  |  | $ 152
Actual %, year-on-year | 42.00% |  |  |  |  |  |  |  |  |  | 45.00%
CER %, year-on-year | 25.00% |  |  |  |  |  |  |  |  |  | 28.00%
Farxiga | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 35 |  |  |  |  |  |  |  |  |  | $ 64
Actual %, year-on-year | 30.00% |  |  |  |  |  |  |  |  |  | 39.00%
CER %, year-on-year | 30.00% |  |  |  |  |  |  |  |  |  | 35.00%
Onglyza |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 126 | 129 | 180 | 127 | 150 | 154 | 149 | 169 | 191 | 211 | $ 255
Actual %, year-on-year | (16.00%) |  |  |  |  |  |  |  |  |  | (16.00%)
CER %, year-on-year | (18.00%) |  |  |  |  |  |  |  |  |  | (19.00%)
Onglyza | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 41 |  |  |  |  |  |  |  |  |  | $ 81
Actual %, year-on-year | 24.00% |  |  |  |  |  |  |  |  |  | 29.00%
CER %, year-on-year | 21.00% |  |  |  |  |  |  |  |  |  | 24.00%
Onglyza | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 49 |  |  |  |  |  |  |  |  |  | $ 98
Actual %, year-on-year | (37.00%) |  |  |  |  |  |  |  |  |  | (38.00%)
Onglyza | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 24 |  |  |  |  |  |  |  |  |  | $ 47
Actual %, year-on-year | (4.00%) |  |  |  |  |  |  |  |  |  | (10.00%)
CER %, year-on-year | (8.00%) |  |  |  |  |  |  |  |  |  | (17.00%)
Onglyza | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 12 |  |  |  |  |  |  |  |  |  | $ 29
Actual %, year-on-year | (14.00%) |  |  |  |  |  |  |  |  |  | (3.00%)
CER %, year-on-year | (21.00%) |  |  |  |  |  |  |  |  |  | (7.00%)
Bydureon |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 155 | 139 | 147 | 128 | 146 | 153 | 142 | 145 | 156 | 135 | $ 294
Actual %, year-on-year | 6.00% |  |  |  |  |  |  |  |  |  | (2.00%)
CER %, year-on-year | 5.00% |  |  |  |  |  |  |  |  |  | (3.00%)
Bydureon | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 7 |  |  |  |  |  |  |  |  |  | $ 7
Actual %, year-on-year | 75.00% |  |  |  |  |  |  |  |  |  | 40.00%
CER %, year-on-year | 125.00% |  |  |  |  |  |  |  |  |  | 40.00%
Bydureon | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 123 |  |  |  |  |  |  |  |  |  | $ 234
Actual %, year-on-year | 6.00% |  |  |  |  |  |  |  |  |  | (4.00%)
Bydureon | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 20 |  |  |  |  |  |  |  |  |  | $ 43
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | 2.00%
CER %, year-on-year | (20.00%) |  |  |  |  |  |  |  |  |  | (10.00%)
Bydureon | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 5 |  |  |  |  |  |  |  |  |  | $ 10
Actual %, year-on-year | (17.00%) |  |  |  |  |  |  |  |  |  | 11.00%
CER %, year-on-year | (17.00%) |  |  |  |  |  |  |  |  |  | 11.00%
Byetta |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 29 | 31 | 48 | 39 | 43 | 46 | 55 | 61 | 76 | 62 | $ 60
Actual %, year-on-year | (33.00%) |  |  |  |  |  |  |  |  |  | (33.00%)
CER %, year-on-year | (35.00%) |  |  |  |  |  |  |  |  |  | (35.00%)
Byetta | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ (1) |  |  |  |  |  |  |  |  |  | $ 4
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | (20.00%)
CER %, year-on-year |  |  |  |  |  |  |  |  |  |  | (60.00%)
Byetta | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 17 |  |  |  |  |  |  |  |  |  | $ 32
Actual %, year-on-year | (39.00%) |  |  |  |  |  |  |  |  |  | (45.00%)
Byetta | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 9 |  |  |  |  |  |  |  |  |  | $ 16
Actual %, year-on-year | (10.00%) |  |  |  |  |  |  |  |  |  | (11.00%)
CER %, year-on-year | (10.00%) |  |  |  |  |  |  |  |  |  | (11.00%)
Byetta | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 4 |  |  |  |  |  |  |  |  |  | $ 8
Actual %, year-on-year | (20.00%) |  |  |  |  |  |  |  |  |  |
CER %, year-on-year | (20.00%) |  |  |  |  |  |  |  |  |  |
Symlin |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 7 | 9 | 13 | 10 | 11 | 14 | 14 | 11 | 10 | 5 | $ 16
Actual %, year-on-year | (36.00%) |  |  |  |  |  |  |  |  |  | (36.00%)
CER %, year-on-year | (36.00%) |  |  |  |  |  |  |  |  |  | (36.00%)
Symlin | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 7 |  |  |  |  |  |  |  |  |  | $ 16
Actual %, year-on-year | (36.00%) |  |  |  |  |  |  |  |  |  | (36.00%)
Crestor |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 338 | 389 | 594 | 580 | 560 | 631 | 631 | 688 | 926 | 1,156 | $ 727
Actual %, year-on-year | (40.00%) |  |  |  |  |  |  |  |  |  | (39.00%)
CER %, year-on-year | (42.00%) |  |  |  |  |  |  |  |  |  | (42.00%)
Crestor | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 186 |  |  |  |  |  |  |  |  |  | $ 424
Actual %, year-on-year | (1.00%) |  |  |  |  |  |  |  |  |  | 9.00%
CER %, year-on-year | (4.00%) |  |  |  |  |  |  |  |  |  | 4.00%
Crestor | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 44 |  |  |  |  |  |  |  |  |  | $ 90
Actual %, year-on-year | 7.00% |  |  |  |  |  |  |  |  |  | (41.00%)
Crestor | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 46 |  |  |  |  |  |  |  |  |  | $ 111
Actual %, year-on-year | (72.00%) |  |  |  |  |  |  |  |  |  | (69.00%)
CER %, year-on-year | (74.00%) |  |  |  |  |  |  |  |  |  | (72.00%)
Crestor | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 62 |  |  |  |  |  |  |  |  |  | $ 102
Actual %, year-on-year | (62.00%) |  |  |  |  |  |  |  |  |  | (64.00%)
CER %, year-on-year | (64.00%) |  |  |  |  |  |  |  |  |  | (66.00%)
Seloken/Toprol-XL |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 173 | 200 | 168 | 160 | 181 | 186 | 178 | 185 | 189 | 185 | $ 373
Actual %, year-on-year | (4.00%) |  |  |  |  |  |  |  |  |  | 2.00%
CER %, year-on-year | (7.00%) |  |  |  |  |  |  |  |  |  | (2.00%)
Seloken/Toprol-XL | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 155 |  |  |  |  |  |  |  |  |  | $ 328
Actual %, year-on-year | 13.00% |  |  |  |  |  |  |  |  |  | 13.00%
CER %, year-on-year | 9.00% |  |  |  |  |  |  |  |  |  | 9.00%
Seloken/Toprol-XL | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 8 |  |  |  |  |  |  |  |  |  | $ 26
Actual %, year-on-year | (58.00%) |  |  |  |  |  |  |  |  |  | (13.00%)
Seloken/Toprol-XL | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 6 |  |  |  |  |  |  |  |  |  | $ 12
Actual %, year-on-year | (71.00%) |  |  |  |  |  |  |  |  |  | (71.00%)
CER %, year-on-year | (71.00%) |  |  |  |  |  |  |  |  |  | (71.00%)
Seloken/Toprol-XL | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 4 |  |  |  |  |  |  |  |  |  | $ 7
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | 17.00%
CER %, year-on-year |  |  |  |  |  |  |  |  |  |  | 17.00%
Atacand |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 66 | 71 | 73 | 80 | 72 | 75 | 81 | 74 | 89 | 71 | $ 137
Actual %, year-on-year | (8.00%) |  |  |  |  |  |  |  |  |  | (7.00%)
CER %, year-on-year | (10.00%) |  |  |  |  |  |  |  |  |  | (10.00%)
Atacand | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 39 |  |  |  |  |  |  |  |  |  | $ 76
Actual %, year-on-year | (5.00%) |  |  |  |  |  |  |  |  |  | (11.00%)
CER %, year-on-year | (2.00%) |  |  |  |  |  |  |  |  |  | (11.00%)
Atacand | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 3 |  |  |  |  |  |  |  |  |  | $ 10
Actual %, year-on-year | (50.00%) |  |  |  |  |  |  |  |  |  | (17.00%)
Atacand | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 19 |  |  |  |  |  |  |  |  |  | $ 41
Actual %, year-on-year | (10.00%) |  |  |  |  |  |  |  |  |  | (2.00%)
CER %, year-on-year | (19.00%) |  |  |  |  |  |  |  |  |  | (12.00%)
Atacand | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 5 |  |  |  |  |  |  |  |  |  | $ 10
Actual %, year-on-year | 25.00% |  |  |  |  |  |  |  |  |  | 25.00%
CER %, year-on-year | 25.00% |  |  |  |  |  |  |  |  |  | 25.00%
CVRM, Others |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 73 | 85 | 80 | 80 | 90 | 89 | 86 | 84 | 106 | 121 | $ 158
Actual %, year-on-year | (19.00%) |  |  |  |  |  |  |  |  |  | (12.00%)
CER %, year-on-year | (23.00%) |  |  |  |  |  |  |  |  |  | (17.00%)
CVRM, Others | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 49 |  |  |  |  |  |  |  |  |  | $ 109
Actual %, year-on-year | (6.00%) |  |  |  |  |  |  |  |  |  | (1.00%)
CER %, year-on-year | (10.00%) |  |  |  |  |  |  |  |  |  | (7.00%)
CVRM, Others | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ (2) |  |  |  |  |  |  |  |  |  | $ (2)
CVRM, Others | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 18 |  |  |  |  |  |  |  |  |  | $ 38
Actual %, year-on-year | (31.00%) |  |  |  |  |  |  |  |  |  | (22.00%)
CER %, year-on-year | (38.00%) |  |  |  |  |  |  |  |  |  | (27.00%)
CVRM, Others | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 8 |  |  |  |  |  |  |  |  |  | $ 13
Actual %, year-on-year | (33.00%) |  |  |  |  |  |  |  |  |  | (35.00%)
CER %, year-on-year | (33.00%) |  |  |  |  |  |  |  |  |  | (35.00%)
Respiratory |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 1,226 | 1,181 | 1,334 | 1,092 | 1,099 | 1,181 | 1,210 | 1,110 | 1,226 | 1,207 | $ 2,407
Actual %, year-on-year | 12.00% |  |  |  |  |  |  |  |  |  | 6.00%
CER %, year-on-year | 7.00% |  |  |  |  |  |  |  |  |  |
Respiratory | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 348 |  |  |  |  |  |  |  |  |  | $ 786
Actual %, year-on-year | 30.00% |  |  |  |  |  |  |  |  |  | 19.00%
CER %, year-on-year | 24.00% |  |  |  |  |  |  |  |  |  | 13.00%
Respiratory | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 404 |  |  |  |  |  |  |  |  |  | $ 675
Actual %, year-on-year | 3.00% |  |  |  |  |  |  |  |  |  | (10.00%)
Respiratory | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 317 |  |  |  |  |  |  |  |  |  | $ 643
Actual %, year-on-year | 9.00% |  |  |  |  |  |  |  |  |  | 9.00%
CER %, year-on-year |  |  |  |  |  |  |  |  |  |  | (2.00%)
Respiratory | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 157 |  |  |  |  |  |  |  |  |  | $ 303
Actual %, year-on-year | 8.00% |  |  |  |  |  |  |  |  |  | 6.00%
CER %, year-on-year | 5.00% |  |  |  |  |  |  |  |  |  | 2.00%
Symbicort |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 672 | 634 | 752 | 668 | 706 | 677 | 740 | 697 | 803 | 749 | $ 1,306
Actual %, year-on-year | (5.00%) |  |  |  |  |  |  |  |  |  | (6.00%)
CER %, year-on-year | (8.00%) |  |  |  |  |  |  |  |  |  | (10.00%)
Symbicort | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 113 |  |  |  |  |  |  |  |  |  | $ 241
Actual %, year-on-year | 12.00% |  |  |  |  |  |  |  |  |  | 13.00%
CER %, year-on-year | 10.00% |  |  |  |  |  |  |  |  |  | 10.00%
Symbicort | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 256 |  |  |  |  |  |  |  |  |  | $ 439
Actual %, year-on-year | (14.00%) |  |  |  |  |  |  |  |  |  | (21.00%)
Symbicort | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 199 |  |  |  |  |  |  |  |  |  | $ 411
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | 3.00%
CER %, year-on-year | (9.00%) |  |  |  |  |  |  |  |  |  | (8.00%)
Symbicort | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 104 |  |  |  |  |  |  |  |  |  | $ 215
Actual %, year-on-year | (3.00%) |  |  |  |  |  |  |  |  |  | (1.00%)
CER %, year-on-year | (6.00%) |  |  |  |  |  |  |  |  |  | (5.00%)
Pulmicort |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 287 | 346 | 371 | 242 | 226 | 337 | 288 | 224 | 239 | 310 | $ 633
Actual %, year-on-year | 27.00% |  |  |  |  |  |  |  |  |  | 12.00%
CER %, year-on-year | 20.00% |  |  |  |  |  |  |  |  |  | 6.00%
Pulmicort | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 212 |  |  |  |  |  |  |  |  |  | $ 482
Actual %, year-on-year | 45.00% |  |  |  |  |  |  |  |  |  | 22.00%
CER %, year-on-year | 37.00% |  |  |  |  |  |  |  |  |  | 15.00%
Pulmicort | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 30 |  |  |  |  |  |  |  |  |  | $ 59
Actual %, year-on-year | (19.00%) |  |  |  |  |  |  |  |  |  | (24.00%)
Pulmicort | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 23 |  |  |  |  |  |  |  |  |  | $ 50
Actual %, year-on-year | 5.00% |  |  |  |  |  |  |  |  |  | 4.00%
CER %, year-on-year | (5.00%) |  |  |  |  |  |  |  |  |  | (6.00%)
Pulmicort | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 22 |  |  |  |  |  |  |  |  |  | $ 42
Actual %, year-on-year | 5.00% |  |  |  |  |  |  |  |  |  | 2.00%
CER %, year-on-year |  |  |  |  |  |  |  |  |  |  | (2.00%)
Fasenra |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 65 | 21 |  |  |  |  |  |  |  |  | $ 86
Fasenra | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 48 |  |  |  |  |  |  |  |  |  | 67
Fasenra | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 6 |  |  |  |  |  |  |  |  |  | 8
Fasenra | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 11 |  |  |  |  |  |  |  |  |  | 11
Daliresp/Daxas |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 45 | 38 | 53 | 53 | 48 | 44 | 41 | 42 | 40 | 31 | $ 83
Actual %, year-on-year | (6.00%) |  |  |  |  |  |  |  |  |  | (10.00%)
CER %, year-on-year | (8.00%) |  |  |  |  |  |  |  |  |  | (12.00%)
Daliresp/Daxas | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ (1) |  |  |  |  |  |  |  |  |  | $ 1
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | (67.00%)
Daliresp/Daxas | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 38 |  |  |  |  |  |  |  |  |  | $ 67
Actual %, year-on-year | (7.00%) |  |  |  |  |  |  |  |  |  | (15.00%)
Daliresp/Daxas | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 7 |  |  |  |  |  |  |  |  |  | $ 14
Actual %, year-on-year | 75.00% |  |  |  |  |  |  |  |  |  | 56.00%
CER %, year-on-year | 75.00% |  |  |  |  |  |  |  |  |  | 44.00%
Daliresp/Daxas | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 1 |  |  |  |  |  |  |  |  |  | $ 1
Tudorza/Eklira |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 39 | 34 | 42 | 37 | 34 | 37 | 36 | 47 | 48 | 39 | $ 73
Actual %, year-on-year | 15.00% |  |  |  |  |  |  |  |  |  | 3.00%
CER %, year-on-year | 12.00% |  |  |  |  |  |  |  |  |  | (3.00%)
Tudorza/Eklira | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ (1) |  |  |  |  |  |  |  |  |  |
Tudorza/Eklira | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 18 |  |  |  |  |  |  |  |  |  | $ 29
Actual %, year-on-year | 29.00% |  |  |  |  |  |  |  |  |  |
Tudorza/Eklira | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 18 |  |  |  |  |  |  |  |  |  | $ 38
CER %, year-on-year | (11.00%) |  |  |  |  |  |  |  |  |  | (11.00%)
Tudorza/Eklira | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 4 |  |  |  |  |  |  |  |  |  | $ 6
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | 50.00%
CER %, year-on-year |  |  |  |  |  |  |  |  |  |  | 50.00%
Duaklir |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 22 | 28 | 23 | 21 | 16 | 19 | 19 | 14 | 17 | 13 | $ 50
Actual %, year-on-year | 38.00% |  |  |  |  |  |  |  |  |  | 43.00%
CER %, year-on-year | 31.00% |  |  |  |  |  |  |  |  |  | 29.00%
Duaklir | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 1 |  |  |  |  |  |  |  |  |  | $ 1
Duaklir | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 20 |  |  |  |  |  |  |  |  |  | $ 47
Actual %, year-on-year | 33.00% |  |  |  |  |  |  |  |  |  | 38.00%
CER %, year-on-year | 13.00% |  |  |  |  |  |  |  |  |  | 24.00%
Duaklir | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 1 |  |  |  |  |  |  |  |  |  | $ 2
Bevespi |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 8 | 5 | 8 | 4 | 3 | 1 | 3 |  |  |  | 13
Bevespi | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | 8 |  |  |  |  |  |  |  |  |  | 13
Respiratory, Others |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 88 | 75 | 85 | 67 | 66 | 66 | 83 | 86 | 79 | 65 | $ 163
Actual %, year-on-year | 35.00% |  |  |  |  |  |  |  |  |  | 23.00%
CER %, year-on-year | 28.00% |  |  |  |  |  |  |  |  |  | 15.00%
Respiratory, Others | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 24 |  |  |  |  |  |  |  |  |  | $ 61
Actual %, year-on-year | 26.00% |  |  |  |  |  |  |  |  |  | 30.00%
CER %, year-on-year | 11.00% |  |  |  |  |  |  |  |  |  | 17.00%
Respiratory, Others | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 6 |  |  |  |  |  |  |  |  |  | $ 1
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | (50.00%)
Respiratory, Others | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 44 |  |  |  |  |  |  |  |  |  | $ 75
Actual %, year-on-year | 33.00% |  |  |  |  |  |  |  |  |  | 23.00%
CER %, year-on-year | 30.00% |  |  |  |  |  |  |  |  |  | 16.00%
Respiratory, Others | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 14 |  |  |  |  |  |  |  |  |  | $ 26
Actual %, year-on-year | 8.00% |  |  |  |  |  |  |  |  |  | 18.00%
CER %, year-on-year |  |  |  |  |  |  |  |  |  |  | 14.00%
Other |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 747 | 929 | 1,094 | 991 | 1,073 | 998 | 1,309 | 1,203 | 1,227 | 1,328 | $ 1,676
Actual %, year-on-year | (30.00%) |  |  |  |  |  |  |  |  |  | (19.00%)
CER %, year-on-year | (33.00%) |  |  |  |  |  |  |  |  |  | (22.00%)
Other | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 291 |  |  |  |  |  |  |  |  |  | $ 557
Actual %, year-on-year | (12.00%) |  |  |  |  |  |  |  |  |  | (15.00%)
CER %, year-on-year | (15.00%) |  |  |  |  |  |  |  |  |  | (16.00%)
Other | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 141 |  |  |  |  |  |  |  |  |  | $ 434
Actual %, year-on-year | (59.00%) |  |  |  |  |  |  |  |  |  | (34.00%)
Other | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 154 |  |  |  |  |  |  |  |  |  | $ 374
Actual %, year-on-year | (25.00%) |  |  |  |  |  |  |  |  |  | (10.00%)
CER %, year-on-year | (29.00%) |  |  |  |  |  |  |  |  |  | (19.00%)
Other | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 161 |  |  |  |  |  |  |  |  |  | $ 311
Actual %, year-on-year | (18.00%) |  |  |  |  |  |  |  |  |  | (8.00%)
CER %, year-on-year | (20.00%) |  |  |  |  |  |  |  |  |  | (12.00%)
Nexium |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 442 | 448 | 427 | 469 | 595 | 461 | 491 | 516 | 562 | 463 | $ 890
Actual %, year-on-year | (26.00%) |  |  |  |  |  |  |  |  |  | (16.00%)
CER %, year-on-year | (28.00%) |  |  |  |  |  |  |  |  |  | (19.00%)
Nexium | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 161 |  |  |  |  |  |  |  |  |  | $ 343
Actual %, year-on-year | (4.00%) |  |  |  |  |  |  |  |  |  |
CER %, year-on-year | (7.00%) |  |  |  |  |  |  |  |  |  | (3.00%)
Nexium | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 87 |  |  |  |  |  |  |  |  |  | $ 187
Actual %, year-on-year | (57.00%) |  |  |  |  |  |  |  |  |  | (45.00%)
Nexium | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 61 |  |  |  |  |  |  |  |  |  | $ 122
Actual %, year-on-year | 3.00% |  |  |  |  |  |  |  |  |  | 2.00%
CER %, year-on-year | (5.00%) |  |  |  |  |  |  |  |  |  | (9.00%)
Nexium | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 133 |  |  |  |  |  |  |  |  |  | $ 238
Actual %, year-on-year | (19.00%) |  |  |  |  |  |  |  |  |  | (6.00%)
CER %, year-on-year | (22.00%) |  |  |  |  |  |  |  |  |  | (9.00%)
Synagis |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 26 | 224 | 234 | 153 | 70 | 230 | 302 | 104 | 27 | 244 | $ 250
Actual %, year-on-year | (63.00%) |  |  |  |  |  |  |  |  |  | (17.00%)
CER %, year-on-year | (63.00%) |  |  |  |  |  |  |  |  |  | (17.00%)
Synagis | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ (9) |  |  |  |  |  |  |  |  |  | $ 125
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | (25.00%)
Synagis | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 35 |  |  |  |  |  |  |  |  |  | $ 125
Actual %, year-on-year | (41.00%) |  |  |  |  |  |  |  |  |  | (6.00%)
CER %, year-on-year | (41.00%) |  |  |  |  |  |  |  |  |  | (6.00%)
Losec/Prilosec |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 76 | 69 | 69 | 66 | 68 | 68 | 59 | 72 | 70 | 75 | $ 145
Actual %, year-on-year | 12.00% |  |  |  |  |  |  |  |  |  | 7.00%
CER %, year-on-year | 4.00% |  |  |  |  |  |  |  |  |  | (1.00%)
Losec/Prilosec | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 42 |  |  |  |  |  |  |  |  |  | $ 88
Actual %, year-on-year | 20.00% |  |  |  |  |  |  |  |  |  | 26.00%
CER %, year-on-year | 9.00% |  |  |  |  |  |  |  |  |  | 16.00%
Losec/Prilosec | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 3 |  |  |  |  |  |  |  |  |  | $ 4
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | (50.00%)
Losec/Prilosec | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 20 |  |  |  |  |  |  |  |  |  | $ 36
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | (5.00%)
CER %, year-on-year | (5.00%) |  |  |  |  |  |  |  |  |  | (13.00%)
Losec/Prilosec | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 11 |  |  |  |  |  |  |  |  |  | $ 17
Actual %, year-on-year | 10.00% |  |  |  |  |  |  |  |  |  | (15.00%)
CER %, year-on-year | 10.00% |  |  |  |  |  |  |  |  |  | (15.00%)
Seroquel XR |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 76 | 53 | 108 | 62 | 95 | 67 | 118 | 190 | 225 | 202 | $ 129
Actual %, year-on-year | (20.00%) |  |  |  |  |  |  |  |  |  | (20.00%)
CER %, year-on-year | (21.00%) |  |  |  |  |  |  |  |  |  | (23.00%)
Seroquel XR | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 22 |  |  |  |  |  |  |  |  |  | $ 40
Actual %, year-on-year | 29.00% |  |  |  |  |  |  |  |  |  | 25.00%
CER %, year-on-year | 35.00% |  |  |  |  |  |  |  |  |  | 22.00%
Seroquel XR | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 33 |  |  |  |  |  |  |  |  |  | $ 49
Actual %, year-on-year | (38.00%) |  |  |  |  |  |  |  |  |  | (36.00%)
Seroquel XR | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 17 |  |  |  |  |  |  |  |  |  | $ 33
Actual %, year-on-year | (19.00%) |  |  |  |  |  |  |  |  |  | (23.00%)
CER %, year-on-year | (29.00%) |  |  |  |  |  |  |  |  |  | (30.00%)
Seroquel XR | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 4 |  |  |  |  |  |  |  |  |  | $ 7
Actual %, year-on-year |  |  |  |  |  |  |  |  |  |  | (30.00%)
CER %, year-on-year |  |  |  |  |  |  |  |  |  |  | (30.00%)
Movantik/Moventig |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 24 | 28 | 30 | 30 | 32 | 30 | 26 | 25 | 23 | 17 | $ 52
Actual %, year-on-year | (25.00%) |  |  |  |  |  |  |  |  |  | (16.00%)
CER %, year-on-year | (25.00%) |  |  |  |  |  |  |  |  |  | (16.00%)
Movantik/Moventig | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 1 |  |  |  |  |  |  |  |  |  | $ 1
Movantik/Moventig | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 23 |  |  |  |  |  |  |  |  |  | $ 51
Actual %, year-on-year | (28.00%) |  |  |  |  |  |  |  |  |  | (18.00%)
Other, Others |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 103 | $ 107 | $ 168 | $ 191 | $ 213 | $ 142 | $ 246 | $ 270 | $ 314 | $ 322 | $ 210
Actual %, year-on-year | (52.00%) |  |  |  |  |  |  |  |  |  | (41.00%)
CER %, year-on-year | (53.00%) |  |  |  |  |  |  |  |  |  | (44.00%)
Other, Others | Emerging Markets |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 65 |  |  |  |  |  |  |  |  |  | $ 85
Actual %, year-on-year | (40.00%) |  |  |  |  |  |  |  |  |  | (60.00%)
CER %, year-on-year | (44.00%) |  |  |  |  |  |  |  |  |  | (54.00%)
Other, Others | US |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 4 |  |  |  |  |  |  |  |  |  | $ 18
Actual %, year-on-year | (90.00%) |  |  |  |  |  |  |  |  |  | 57.00%
Other, Others | Europe |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 21 |  |  |  |  |  |  |  |  |  | $ 58
Actual %, year-on-year | (54.00%) |  |  |  |  |  |  |  |  |  | (30.00%)
CER %, year-on-year | (54.00%) |  |  |  |  |  |  |  |  |  | (51.00%)
Other, Others | Established ROW |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ 13 |  |  |  |  |  |  |  |  |  | $ 49
Actual %, year-on-year | (28.00%) |  |  |  |  |  |  |  |  |  | (11.00%)
CER %, year-on-year | (22.00%) |  |  |  |  |  |  |  |  |  | (20.00%)

X
- Definition Represents the increase (decrease) in revenue based on constant exchange rate, year-on-year, as a percent. + References No definition available. + Details
Name: | azn_IncreaseDecreaseInRevenueConstantExchangeRateYearOnYearAsPercentage
Namespace Prefix: | azn_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the actual increase (decrease) in revenue, year-on-year, as a percent. + References No definition available. + Details
Name: | azn_IncreaseDecreaseInRevenueYearOnYearPercentage
Namespace Prefix: | azn_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2018-01-01 -Name IFRS -Number 15 -IssueDate 2017-01-01 -Paragraph 113 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=15&date=2017-03-01&anchor=para_113_a&doctype=Standard -URIDate 2017-03-09 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2018-01-01 -Name IFRS -Number 15 -IssueDate 2017-01-01 -Paragraph 114 -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=15&date=2017-03-01&anchor=para_114&doctype=Standard -URIDate 2017-03-09 + Details
Name: | ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=azn_EmergingMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=azn_IfrsCountryUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=azn_IfrsEuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=azn_WorldExcludingEmergingMarketsUnitedStatesAndEuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_OncologyProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_TagrissoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_IressaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_LynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_ImfinziMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_CalquenceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_FaslodexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_ZoladexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_ArimidexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_CasodexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_OtherOncologyProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_CardiovascularRenalAndMetabolismProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_BrilintaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_FarxigaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_OnglyzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_BydureonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_ByettaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_SymlinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_CrestorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_SelokenToprolXlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_AtacandMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_OtherCardiovascularRenalAndMetabolismProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_RespiratoryProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_SymbicortMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_PulmicortMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_FasenraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_DalirespDaxasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_TudorzaEkliraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_DuaklirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_BevespiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_OtherRespiratoryProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_OtherProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_NexiumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_SynagisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_LosecPrilosecMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_SeroquelXrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_MovantikMoventigMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_OtherProductsOthersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |